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About 80% of all pancreatic cancer patients suffer from a wasting syndrome defined as the cancer cachexia characte- 
rized by abnormally low weight, weakness, and loss of skeletal muscle mass, which directly impacts physical activity, 
quality of life and overall survival. Over the past decades, we have gained new insights into the underlying mechanism 
of cachexia associated with pancreatic cancer. The aim of this review was to explore recent findings about cancer cache-
xia pathophysiology and describe the current pharmacologic approach. Pancreatic cancer cachexia is a multifactorial synd-
rome mediated by mechanical factors, inflammatory cytokines, neuropeptides, hormones and tumor-derived factors. 
The treatment of cancer cachexia remains controversial but is currently an active area of research. Several new targeted 
drugs are under investigation, and we hope to open a new prospect in the management of cancer cachexia in the future.
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INTRODUCTION
Cachexia is a multifactorial syndrome with ongoing loss 
of skeletal muscle mass, with or without loss of fat mass that 
cannot be fully reversed by conventional nutritional support 
and leads to progressive functional impairment.1 It can occur 
in the course of chronic benign disease such as congestive 
heart failure or human immunodeficiency virus (HIV) infe- 
ction. However, it is most frequently observed in patients with 
malignancy, especially in advanced stage of disease. Many pa-
tients with advanced cancer suffer from a wasting syndrome 
characterized by anorexia, loss of weight, sarcopenia, and a 
poor prognosis, defined as the cancer anorexia-cachexia synd- 
rome.2
Cachexia is highly prevalent in pancreatic cancer, and up 
to 80% of pancreatic cancer patients undergo severe cachexia 
at the time of death.3,4 This wasting syndrome is related with 
poor tolerability of cancer treatment, and furthermore, it can 
reduce quality of life and expected survival of the patients.5-7 
In addition, preoperative existence of cachexia in pancreatic 
cancer patients has been associated with poor outcome after 
pancreatoduodenectomy.8
Although new insights into the pathogenesis of cancer cache- 
xia have been gained over the past decades, the underlying 
mechanisms are still poorly understood. It is currently to be an 
active area of research for potential treatment targets of can-
cer cachexia. We believed that improvement in overall survival 
or quality of life in pancreatic cancer patients could be achie- 
ved from a better management of cachexia. This article revi- 
ews the current concepts and therapeutic approach of this 
disabling phenomenon.
1. Definition and classification of cancer cachexia
The consensus diagnostic criteria of cancer cachexia defi- 
ned as a case of (1) involuntary weight loss more than 5% 
in the last 6 months if no starvation present; (2) weight loss 
more than 2% in individuals with body mass index (BMI less 
than 20 kg/m2; or (3) weight loss more than 2% along with 
skeletal muscle index (SMI) consistent with sarcopenia (males 
<7.26 kg/m2, females <5.45 kg/m2) (Table 1). Any direct mea- 
sure of skeletal muscle mass (dual-energy X-ray absorptiom-
etry (DEXA), computed tomography (CT), magnetic resona- 
nce imaging (MRI)) is recommended in case of fluid reten- 
tion, massive tumor load or obesity.9
SH Lee, et al. Cancer Cachexia in Pancreatic Cancer Patients
62 www.gicancer.or.kr
Table 1. Diagnosis of cancer cachexia
Weight loss greater than 5% over the past 6 months; or
Weight loss greater than 2% in individuals with BMI less than 
20 kg/m2; or
Evidence of sarcopenia*withweightlossgreaterthan 2%
*Sarcopenia defined as appendicular skeletal muscle index in 
 males <7.26 kg/m2and infemales <5.45 kg/m2 determined by
 DEXA.
Mechanical factors
• Dysphagia/odynophagia
• Nausea/vomiting
• Pancreatic insufficiency
• Pain
• Constipation
• Bowel obstruction
Tumor-derived factors
• Lipid mobilizing factor
• Proteolysis inducing 
factor
Peripheral 
pathways 
Humoral factor 
• Cytokine: IL-1, IL-6, TNF-α
• Neuropeptide : NPY, serotonin,
melanocortin
• Hormone: insulin, glucagon,
leptin
Central mediated pathway 
(Hypothalamus)
↑ Lipolysis, ↑ Proteolysis,↑ Lipid mobilization,
↑ Energy expenditure 
Anorexia
Cancer cachexiai
Neural 
invasion
• Astrocyte
activation
Fig. 1. Pathopysiology of cachexia in pancreatic cancer. There are several factors which contribute to develop cachexia
in pancreatic cancer, including mechanical factors, tumor-derived factors, humoral factors and neuronal invasion. 
Several pro-inflammatory cytokines, circulating hormones, neuropeptides, and neurotransmitters result in anorexia
and metabolic alteration, such as increased lipolysis, proteolysism lipid mobilization and energy.
*Adapted from Tan et al. Front Physiol 2014;5:88.1
This international consensus also described three stages of 
cachexia; precachexia, cachexia, and refractory cachexia.9 
Severity is based on the degree of depletion of energy store 
and body protein mass (using BMI) and the rate of ongoing 
weight loss. In precachexia, patients with early clinical and 
metabolic signs including anorexia and impaired glucose tol-
erance can precede considerable involuntary weight loss. Some 
patients then have progressive weight loss and meet the crite- 
ria for cachexia as previously defined. Large retrospective 
cohort study for pancreatic cancer revealed that a reduction 
in BMI developed as early as 3 years prior to cancer diagnosis 
and cachexia-associated symptoms presented at average 2 
months before the cancer diagnosis.10,11 Unfortunately, most 
patients with pancreatic cancer usually demonstrate in the 
advanced stage with cachexia symptoms,12 and their cachexia 
becomes clinically refractory as a result of progressive unres- 
ponsive to cancer treatment. In refractory cachexia stage, pa-
tients have worsening performance status with expected sur-
vival less than 3 months.
2. Pathophysiology of cancer cachexia
Cancer cachexia arises from a complex interaction between 
cancer growth and host response resulting ongoing weight 
loss, a consequence of a negative protein and energy balance 
mediated by a combination of reduced food intake and increa- 
sed metabolism.1,9 The pathophysiology includes a series of 
complex metabolic mechanisms directly related to the tumor- 
host interaction (Fig. 1). There are mechanical factors that 
contribute to reduced food intake, tumor-derived factors re-
leased from the tumor itself and humoral factors generated 
as the host’s biological response to the tumor. Several pro-in-
flammatory cytokines, circulating hormones, neuropeptides, 
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and neurotransmitters can affect the development of cancer 
cachexia.13 In addition recent studies have described the other 
potentially momentous processes involved in the develop-
ment of pancreatic cancer cachexia, including astrocytic acti-
vation from neural invasion of pancreatic cancer.14,15
3. Mechanical factors
Mechanical digestive abnormalities that can reduce food 
intake and result in a lack of appetite include abdominal pain, 
nausea, dysphagia, odynophagia, pancreatic insufficiency, con- 
stipation, and intestinal obstruction.16 They can induce and 
maintain cancer-associated weight loss. These symptoms re-
sult from direct cancer invasion to pancreatic duct and/or gast- 
rointestinal tract, particularly the duodenal second portion. 
Also, some patients who received the resection of pancreas 
suffer from pancreatic insufficiency and poor oral intake.
4. Humoral factors
The humoral mediators of cancer cachexia include pro-in-
flammatory cytokines (interleukin-1 (IL-1), interleuin-6 (IL-6), 
interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α), neu-
ropeptides (neuropeptide Y, serotonin, melanocortin) and 
hormones (insulin, glucagon, leptin). These pathways can be 
divided into central pathways, which are controlled at brain 
hypothalamus, and peripheral pathways, which associate with 
direct lipolysis and proteolysis.
1) Centrally-mediated pathways
Recent evidence suggests that systemic inflammation plays 
a pivotal role in inducing cancer anorexia by triggering a com- 
plex neurochemical pathways in hypothalamus.17,18 Increased 
cytokine expression prevents the activation of hypothalamus 
from responding appropriately to peripheral signals by persis-
tent stimulation of anorexigenic pathways and inhibition of 
orexigenic pathways.19,20 Some studies reveal that cancer cache- 
xia is associated with hyperactivation of the pro-opiomelno-
cortin (POMC)/cocaine and amphetamine-regulated transc- 
ript (CART) pathways (one of anorexigneic pathways) which 
may be triggered by IL-1 and other pro-inflammatory cyto- 
kines.21-24
Leptin is a protein with homeostatic effect released by fatty 
tissue, which reduces appetite and increase energy expendi- 
ture through the central nervous system (CNS). In situation 
of weight loss, leptin release is decreased and this stimulation 
the appetite in the CNS by activation of neuropeptide Y (NRY)/ 
Agouti-related peptide (AgRP) pathway (one of orexigenic path- 
ways) and reduced activity of anorexigenic neuropeptide, such 
as corticotropin-releasing factor (CRF) and melanocortin. Cur- 
rent studies for cancer cachexia suggest that inflammatory 
cytokine like IL-1 and TNF-α activate the leptin signaling and 
disturb the orexigenic response to decreased peripheral leptin 
level.19,25
Serotonin also may play an important role in the develop-
ment of cancer anorexia through the melanocortin system. 
Studies suggested that IL-1 stimulates the release of hypotha- 
lamic serotonin, which contribute to the persistent activation 
of POMC/CARD pathway, resulting in decreased appetite and 
anorexia.26,27
2) Peripheral pathways
Inflammatory cytokines not only contribute to the neuro-
chemical changes in the CNS responsible for anorexia, but 
also have been revealed to induce proteolysis, lipolysis, and 
the hepatic acute phase protein response (APPR) through the 
numerous pathways. These processes develop the uncompen- 
sated loss of muscle and adipose tissue.
TNF-α is one of the first identified as an endogenous cache- 
xia-inducing factors. TNF-α stimulates protein degradation 
in the proteasome-ubiquitin system, mediated by transcrip- 
tion factors, such as nuclear factor kappa B (NF-κB) and 
MyoD.28-30 Some studies also showed that TNF-α promote 
lipolysis in vitro with increase in glycerol release in mouse 
and human adipocyte, through downregulation of perilipin exp- 
ression, which subsequently induce hormone-sensitive lipase 
(HSL), a key regulator of lipolysis, to access the surface of lipid 
droplets for breakdown.31,32 Additionally, TNF-α has a inhibi- 
tory action on adipocyte differentiation, resulting in impaired 
lipogenesis.33,34
IL-6 is another important cytokine in the development of 
cachexia in pancreatic cancer, particularly associated with acti- 
vation of the hepatic APPR. Moses et al found that overpro- 
duction of IL-6 and elevated APPR (for example; elevated 
c-reactive protein (CRP) level) have been significantly asso-
ciated with decreased survival in patients with pancreatic cancer 
cachexia.35There is strong relationship between increased 
IL-6 production of peripheral blood mononuclear cells and 
the presence of elevated APPR.35-37 The activation of hepatic 
APPR promote the mobilization of peripheral amino acid sto- 
res, mostly from skeletal muscle, contributing to the loss of 
lean body mass. 
5. Tumor factors
In addition to several humoral factors such as cytokines, 
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hormones and neurotransmitters, tumor-derived factors con-
tribute to metabolic dysregulation in pancreatic cancer cache- 
xia. There are two most well studied factors, lipid mobilizing 
factor (LMF) and proteolysis-inducing factor (PIF).
LMF was first discovered from a cachexia-inducing murine 
tumor model and the urine of patients with unresectable pan-
creatic cancer with weight loss.38 This material was 43 kDa 
and was suggest to be homologous with the plasma protein 
zinc-α2-glycoprotein (ZAG).38 LMF/ZAG not only induces 
lipid mobilization through various signal pathways but also 
augment substrate utilization and activates mitochondrial oxi-
dative pathways in brown adipose tissue. Consequently, LMF/ 
ZAG causes lipolysis with increased energy expenditure, and 
catatbolism.39-41 Recently, LMF/ZAG is proposed as a serum bio- 
marker in pancreatic cancer cachexia.42
PIF was isolated in 1996 from a mouse tumor model of 
cachexia, as a 24 kDa glycoprotein inducing skeletal muscle 
catabolism.43 PIF was detected in the urine of 80% of pan- 
creatic cancer patients with cachexia, and rate of weight loss 
was greater in patients who  have PIF in their urine.44 Also, 
when PIF from urine of cancer cachexia patients administered 
intravenously to normal mice, PIF induced significant weight 
loss without reduction in food and water intake.45 Some studies 
suggest that PIF-mediated protein degradation may be media- 
ted by the ubiquitin-proteasome proteolytic pathway in skel-
etal muscle; that process results from activation of NFκB.46-48 
Also, PIF inhibits the protein synthesis on skeletal muscle 
through activation of double-stranded RNA dependent pro-
tein kinase (PKR).49
6. Other mechanisms
Recent studies have suggested that neural invasion of pan-
creatic cancer is related to astrocyte activation and develop-
ment of cachexia in pancreatic cancer patients.14,15 Neuronal 
invasion of pancreatic cancer induce the activation of astrocy- 
tes and microglia in the spinal cord. These activated astrocy- 
tes can subsequently develop lipolysis and muscle atrophy 
in pancreatic cancer patients, although more researches is nee- 
ded to determine the underlying mechanisms involving cache- 
xia.14
7. Treatment of cancer cachexia
The primary end-points of optimal treatment of cancer cache- 
xia are improvements in cachexia-associated symptoms such 
as anorexia and fatigue, lean body mass, resting energy expen- 
diture, quality of life, and performance status through inhi- 
bition of effect of pro-inflammatory cytokines.50 Although 
there has been recently remarkable advances in preclinical and 
clinical research in era of cancer cachexia , the currently avail-
able treatment options are still limited. 
8. Nutritional support
Nutritional risk is highest among pancreatic cancer patients.51 
However, despite several trials of conventional and/or aggre- 
ssive nutritional support using different feeding techniques, 
the cachectic state is difficult to be overcomed by nutritional 
support alone.52 A small multicenter randomized trial for pa-
tients with advanced pancreatic cancer showed a meaningful 
improvement in weight and body mass composition as well 
as quality of life with L-Carnitine supplementation.53
9. Pharmacologic treatment
The two major options for pharmacological therapy have 
been, till now, either progestational agents or corticosteroids. 
Recently, there are various drugs studied for treatment of can- 
cer cachexia. 
Megestrol acetate is semi-synthetic progesterone widely used 
as an appetite stimulant. The pharmacologic activity of mege- 
strol acetate was considered as reduced release of pro-inflam- 
matory cytokines (IL-1, IL-6, TNF-α) and stimulation of NPY 
in the hypothalamus.54,55 Several randomized control trials 
have demonstrated that megestrol acetate (480-800 mg/ day) 
significantly improves appetite, nausea, food intake, and weight 
gain among patients with cancer cachexia, including those 
with pancreatic cancer.56-59 Megestrol acetate is generally well- 
tolerated with low incidence of adverse events, such as skin 
rash, hyperglycemia, adrenal insufficiency, and thromboem-
bolic events.57 Since its approval in 1993, several meta-anal-
yses have revealed that megestrol acetate has better effect of 
improved appetite, weight, and quality of life compared than 
placebo or other drugs (cisapride, dronabinol, corticosteroids, 
nandrolone).60,61
Corticosteroids, such as dexamethasone, have been studied 
to treat cancer-associated anorexia and cachexia.62,63 The me- 
cha nism of action is likely associated with the inhibition of 
IL-1, TNF-α, and leptin as well as the stimulation of NPY.64 
However, the effects of corticosteroid could not be maintai- 
ned longer than 4 weeks and related to long-term side effects, 
such as insulin resistance, fluid retention, steroid-induced 
myopathy, skin fragility, adrenal insufficiency, and sleep and 
cognitive disorders.65Owing to their short term symptomatic 
benefits with long term adverse effects, corticosteroids are 
just considered as treatment option in patients with short 
expected survival. 
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Dronabinol is effective in reducing nausea and increasing 
appetite with a tendency to weight stabilization. The appe-
tite-stimulant effect of dronabinol associated with interaction 
with endorphin receptors, interference with IL-1 synthesis, 
activation of cannabinoid receptors involved in the neuronal 
circuit of leptin and inhibition of prostaglandin synthesis.20 
A phase II study showed that dronabinol decreased anorexia 
in 68% of patients, but 16% of patients had to stop admin-
istration due to CNS adverse events, such as euphoria, hallu-
cinations, psychosis, and vertigo.66 However, in result of first 
clinical trial that compared megestrol acetate with dronabi-
nol, megestrol acetate was appears to be superior to dronabi-
nol in aspect of increasing appetite and weight gain.67 Drona- 
binol serves as an alternative treatment option as an appetite 
stimulant and anti-emetic.
Non-steroidal anti-inflammatory drugs (NSAIDs), includ-
ing cyclooxygenase-2 (COX-2) inhibitors, ibuprofen, and in-
domethacin, reduce release of acute phase proteins and pro- 
inflammatory cytokines.68,69 NSAIDs are suggested to inhibit 
prostaglandin synthesis and thereby prevent downstream ef-
fects of systemic inflammation. Preliminary results of some 
studies for NSAIDs, such as indomethacin and ibuprofen, 
have been shown to effect to increase weight and muscle mass, 
improve quality of life, and prolong survival in advanced can-
cer patients, especially when combined with progestogens.69-72 
However, further large studies are needed to validate the 
clinical role of NSAIDs in the management of cancer cachexia. 
Thalidomide have anti-inflammatory and immunomodula- 
tory properties that downregulate the production of TNF-α 
and other cytokines, inhibit NF-κB, downregulate COX-2, 
and inhibit aniogenesis.73 In 2005, Gorden et al. published 
the results of a single center, double blinded, placebo-control- 
led, randomized study aimed at assessing the efficacy and 
safety of thalidomide in attenuating weight loss in pancreatic 
cancer patients with cachexia.74 The study population consis- 
ted of 50 patients (who had lost at least 10% of their body 
weight) randomized to administer thalidomide 200 mg/day or 
a placebo for 24 weeks. The conclusion of the study strongly 
suggested that thalidomide was effective for attenuating loss 
of weight and lean body mass in patients with cancer cache- 
xia. Thalidomide was typically well-tolerated. Adverse events 
included peripheral neuropathy, dizziness, somnolence, con-
stipation, rash, and possible increased risk of venous throm- 
boembolism. These results are significant but further large- 
scale clinical trials are needed to validate the efficacy of thali-
domide in treating pancreatic cancer cachexia.
Cyproheptadine is an antiserotoninergic agent with anti-
histamine properties. Despite some promising results of pilot 
studies, controlled clinical trials have not yet proved its effi-
cacy in cancer cachexia patients.75,76 Pizotifen is an antisero- 
toninergic drug studied in the treatment of anorexia asso-
ciated with other benign causes, which has not been inves-
tigated in cancer patients.
Eicosapentaenoic acid (EPA) and docosahexaenoic acid 
(DHA), a long-chain polyunsaturated fatty acid of the ome-
ga-3 family, are have been revealed to suppress production 
of pro-inflammatory cytokines, including IL-1, TNF-α, and 
IL-6.77,78 EPA can also inhibit the downstream effect of LMF 
and PIF.79-81 Their efficacy in cancer cachexia has not been 
fully validated in well-organized clinical trials.82-84 Two sys-
tematic literature reviews conclude the EPA and DHA in 
monotherapy show no significant improvement in appetite, 
fat free mass, survival and quality of life compared with pla- 
cebo.85,86 The efficacy of EPA in cancer cachexia treatment 
remains uncertain although recent study suggest that EPA 
supplementation may not be effective as a single agent or even 
in combination with megestrol acetate in patients with cancer 
cachexia.
Current studies are investigating an approach of drug com-
binations to attenuate cancer cachexia. A recent data from a 
large multicenter trial with 332 patients comparing medroxy- 
progesterone, megestrol acetate, and oral supplementation 
with EPA, L-carnitine, and thalidomide found that the combi-
nation therapy was significantly effective in improving lean 
body mass and appetite than any other treatment arms with 
single drug treatment.87
10. New therapeutic targets
Due to lack of the available drugs that have shown sustai- 
ned effects on weight stabilization and improvement in sur-
vival, various researches have continued to explore new ther-
apeutic targets and to develop new drugs. 
OHR/AVR 118 is a recently developed, broad-spectrum 
peptide-nucleic acid immunomodulator that target both TNF-
α and IL-6. A phase II study including patients with advanced 
cancer and cachexia presented an improvement in anorexia, 
dyspepsia, strength anddepression.88 A phase IIb study is cur- 
rently underway to evaluate the safety and efficacy of OHDR/ 
AVR118(NCT01206335). 
ALD518 (also known as BMS-945429), a humanized mon-
oclonal IL-6 antibody, showed promising beneficial results 
in phase II randomized, double-blinded, placebo-controlled 
trials with non-small cell lung cancer (NSCLC) patients with 
cachexia.89,90 This agent was safe and well tolerated. ALD518 
has effect of increasing hemoglobin level and preventing loss 
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of lean body mass with significant improvement of fatigue 
score.89,90
Ghrelin is the endogenous ligand of the growth hormone 
receptor that produces the release of growth hormone and 
NPY.91 In addition, Ghrelin induces the release of anti-inflam- 
matory cytokine, IL-10, which suppressed the production of 
pro-inflammatory cytokines, including IL-1β, Il-6 and TNF-
α.92-94 Several controlled clinical trials using oral ghrelin mim-
etic named RC-1291 or anamorelin, demonstrated an impro- 
vement in increasing appetite and weight in cancer cachexia 
patients.95-97 Macimorelin is a novel oral ghrelin compound, 
with a good oral availability and stability, which binds the 
growth hormone secretagogue receptor (GHSR) 1a with simi- 
lar affinity to ghrelin.98 These findings promoted further inves 
tigation for ghrelin analogs andmore phase II trials are ongo- 
ing (NCT01505764, NCT01614990). 
MT-102, a novel anabolic/catabolic transforming agent, has 
a multi-targeting effect on three potential pharmacological 
pathways in cancer cachexia, primarily reduced catabolism 
through nonselective β-blockade, improve fatigue and ther-
mogenesis through blocking central 5-HT 1a receptor, and 
increased anabolism through partial activation of β-2 recep- 
tor.99 Two phase II studies in stage III/IV colorectal cancer and 
NSCLC are under investigation (ACT-ONE and ACT-TWO; 
NCT01238107).99
BYM338 (bimagrumab) is a fully humanized monoclonal 
antibody blocking the activin II receptor type IIB (ActRIIB) 
and preventing receptor occupation by myostatin. Myostatin, 
a member of the TGF-β superfamily, is expressed almost exclu- 
sively in skeletal muscle and acts as a negative regulator of 
muscle growth, through binding to the ActRIIB by activating 
multiple downstream pathways.100 Inhibition of muscle diffe- 
rentiation by myostatin is mediated, in part, through Smad 
2/3 phosphorylation-dependent inhibition of the Akt/mTOR 
pathway.100 In preclinical study, ActRIIB blockade prevented 
muscle loss and prolonged survival in C-26 tumor-bearing 
mice.101 A multicenter, randomized, double-blind, placebo- 
controlled phase II trials to investigate the efficacy of BYM 
338 in attenuating loss of body mass in cachectic patients with 
stage IV NSCLC or stage III/IV pancreatic cancer has been comple- 
ted and in preparation to report the results (NCT01433263). 
LY2495655 is another humanized anti-myostatin antibody 
currently under investigation. A phase II study in patients with 
locally advanced or metastatic pancreatic cancer is ongoing 
to evaluate two different doses of LY2495655 in combination 
with standard of care chemotherapy in improving survival, 
lean body mass and physical performance (NCT01505530).
CONCLUSION
Although cachexia is a major problem in cancer and many 
chronic diseases, cachexia treatment is still largely ignored 
even for inpatient management or limited to dietary counsel-
ing to treat weight loss with poor efficacy. Regarding that 
approximately 80% of pancreatic cancer suffer from cachec-
tic symptoms and up to 30% die from cachexia-related com-
plications, importance of treatment for cancer cachexia, espe-
cially in pancreatic cancer patients, should be acquired in 
the future.1,102 Although pancreatic cancer cachexia is consid-
ered as multifactorial syndrome mediated by mechanical fac-
tors, pro-inflammatory cytokines, neuropeptides, hormones 
and tumor-derived factors, further researches to understand 
the basic mechanism involved in induction and maintenance 
of pancreatic cancer cachexia are further needed. Recently, 
some preliminary studies for targeted agents have been shown 
promising results. We hoped that new therapeutic strategies 
will be developed to improve the quality of lifer and prolong 
the survival of pancreatic cancer patients in the future. 
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